239 related articles for article (PubMed ID: 35417234)
1. When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.
Hasim MS; Marotel M; Hodgins JJ; Vulpis E; Makinson OJ; Asif S; Shih HY; Scheer AK; MacMillan O; Alonso FG; Burke KP; Cook DP; Li R; Petrucci MT; Santoni A; Fallon PG; Sharpe AH; Sciumè G; Veillette A; Zingoni A; Gray DA; McCurdy A; Ardolino M
Sci Adv; 2022 Apr; 8(15):eabj3286. PubMed ID: 35417234
[TBL] [Abstract][Full Text] [Related]
2. Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
Pagliano O; Morrison RM; Chauvin JM; Banerjee H; Davar D; Ding Q; Tanegashima T; Gao W; Chakka SR; DeBlasio R; Lowin A; Kara K; Ka M; Zidi B; Amin R; Raphael I; Zhang S; Watkins SC; Sander C; Kirkwood JM; Bosenberg M; Anderson AC; Kuchroo VK; Kane LP; Korman AJ; Rajpal A; West SM; Han M; Bee C; Deng X; Schebye XM; Strop P; Zarour HM
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35316223
[TBL] [Abstract][Full Text] [Related]
3. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells.
Campos-Mora M; Jacot W; Garcin G; Depondt ML; Constantinides M; Alexia C; Villalba M
Front Immunol; 2023; 14():1199594. PubMed ID: 37593736
[TBL] [Abstract][Full Text] [Related]
4. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
5. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
6. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
7. Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.
Lu T; Ma R; Li Z; Mansour AG; Teng KY; Chen L; Zhang J; Barr T; Caligiuri MA; Yu J
Cancer Immunol Res; 2021 Oct; 9(10):1229-1241. PubMed ID: 34326137
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes and Trogocytosis-Mediated Signaling.
Reed J; Reichelt M; Wetzel SA
Cells; 2021 Jun; 10(6):. PubMed ID: 34204661
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
11. NK cells limit therapeutic vaccine-induced CD8
Diniz MO; Schurich A; Chinnakannan SK; Duriez M; Stegmann KA; Davies J; Kucykowicz S; Suveizdyte K; Amin OE; Alcock F; Cargill T; Barnes E; Maini MK
Sci Transl Med; 2022 Apr; 14(640):eabi4670. PubMed ID: 35417187
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.
Pesce S; Greppi M; Tabellini G; Rampinelli F; Parolini S; Olive D; Moretta L; Moretta A; Marcenaro E
J Allergy Clin Immunol; 2017 Jan; 139(1):335-346.e3. PubMed ID: 27372564
[TBL] [Abstract][Full Text] [Related]
13. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.
Del Rio ML; Perez-Simon JA; Rodriguez-Barbosa JI
Front Immunol; 2022; 13():887348. PubMed ID: 35795681
[TBL] [Abstract][Full Text] [Related]
14. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
15. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection.
Norris S; Coleman A; Kuri-Cervantes L; Bower M; Nelson M; Goodier MR
Viral Immunol; 2012 Aug; 25(4):329-32. PubMed ID: 22742708
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
[TBL] [Abstract][Full Text] [Related]
17. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB
J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842
[TBL] [Abstract][Full Text] [Related]
18. Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis.
Shin JH; Jeong J; Maher SE; Lee HW; Lim J; Bothwell ALM
Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819374
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
20. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
